Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Top Cited Papers
- 7 April 2020
- journal article
- review article
- Published by S. Karger AG in Psychotherapy and Psychosomatics
- Vol. 89 (5), 283-306
- https://doi.org/10.1159/000506868
Abstract
Studies on psychotropic medications decrease, discontinuation, or switch have uncovered withdrawal syndromes. The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class (i.e., benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, antidepressants, ketamine, antipsychotics, lithium, mood stabilizers) according to the diagnostic criteria of Chouinard and Chouinard [Psychother Psychosom. 2015;84(2):63–71], which encompass new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. All these drugs may induce withdrawal syndromes and rebound upon discontinuation, even with slow tapering. However, only selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, and antipsychotics were consistently also associated with persistent post-withdrawal disorders and potential high severity of symptoms, including alterations of clinical course, whereas the distress associated with benzodiazepines discontinuation appears to be short-lived. As a result, the common belief that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature. Ketamine, and probably its derivatives, may be classified as at high risk for dependence and addiction. Because of the lag phase that has taken place between the introduction of a drug into the market and the description of withdrawal symptoms, caution is needed with the use of newer antidepressants and antipsychotics. Within medication classes, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, and quetiapine are more likely to induce withdrawal. The likelihood of withdrawal manifestations that may be severe and persistent should thus be taken into account in clinical practice and also in children and adolescents.Keywords
This publication has 199 references indexed in Scilit:
- A Case Report of Onset of Tinnitus Following Discontinuation of Antidepressant and a Review of the LiteratureThe Primary Care Companion For CNS Disorders, 2012
- The mechanisms of tolerance in antidepressant actionProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosisJournal of Psychopharmacology, 2010
- Cascade iatrogenesis: Factors leading to the development of adverse events in hospitalized older adultsInternational Journal of Nursing Studies, 2009
- Ketamine AddictionAnesthesiology, 1987
- Effect of Gradual Withdrawal on the Rebound Sleep Disorder after Discontinuation of TriazolamNew England Journal of Medicine, 1987
- Withdrawal Reaction after Long-Term Therapeutic Use of BenzodiazepinesNew England Journal of Medicine, 1986
- Comparative Hypnotic Effects of Flurazepam, Triazolam, and PlaceboJournal of Clinical Psychopharmacology, 1984
- Flurazepam for Short‐Term Treatment of Complaints of InsomniaThe Journal of Clinical Pharmacology, 1982
- Effectiveness of Temazepam with Short‐, Intermediate‐, and Long‐Term Use: Sleep Laboratory EvaluationThe Journal of Clinical Pharmacology, 1978